Summary terms of the offering include securities offered of units consisting of one share of common stock and four-tenths of a warrant to purchase one share of common stop. Maximum of 2,490,080 units subject to 20% Nasdaq issuance restriction, with approximately $11.0 million in gross proceeds
Neuro-Hitech is a publicly-traded (NasdaqCM: NHPI) biotechnology company focused on developing therapies for the treatment of Alzheimer’s disease and other neurodegenerative disorders. NHPI went public via a reverse merger in January 2006. The Company is currently evaluating its lead product, Huperzine A, for safety and efficacy in a Phase II clinical trial for the treatment of mild to moderate Alzheimer’s disease. Huperzine A is a cholinesterase inhibitor, which is a well established mechanism of action, and is derived from the club moss Huperzia serrata, which has been used for centuries in China to treat cognitive disorders, fevers and inflammation.
About M.M. Dillon & Co.
M.M. Dillon & Co. (formerly CRT Investment Banking LLC) is an employee owned partnership where industry and product specialists collaborate closely to provide creative, idea-driven advice and solutions to its institutional and corporate clients. M.M. Dillon offers public and private financing, M&A advisory and restructuring advisory services. M.M. Dillon’s team of experienced professionals provides execution capabilities for companies across a range of industry sectors. The firm’s senior banking professionals have a minimum of 20 years of experience with major Wall Street firms.